Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Succeeder Technology Inc. (688338.SS)
Beijing, CN
Beijing Succeeder Technology Inc. specializes in the development, production, and distribution of in-vitro diagnostic (IVD) products, serving markets both domestically within China and internationally. The company provides a comprehensive portfolio of diagnostic equipment, including coagulation analyzers and their associated reagents, blood rheology analyzers, erythrocyte sedimentation rate (ESR) analyzers, and platelet aggregation analyzers. Established in 2003, its main operational base is located in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.29% | -8.42% | -13.60% | -22.21% | -2.77% | +0.43% | +7.75% | -35.46% | -44.12% | -80.15% | -80.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-13.8% Q1'26: -12.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-20.6% Q1'26: -13.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+26.7% Q1'26: +13.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+39.1% ★ Q1'26: +38.4% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+21.9% ★ Q1'26: +18.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-1.6% ★ Q1'26: -3.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
305.87M
est: 305.00M (+0.3%)
|
263.67M
est: 359.00M (-26.6%)
|
424.00M
424.00M – 424.00M
+18.1% YoY
|
502.00M
502.00M – 502.00M
+18.4% YoY
|
| EBITDA |
141.58M
est: 150.55M (-6.0%)
|
114.77M
est: 177.20M (-35.2%)
|
209.29M
209.29M – 209.29M
+18.1% YoY
|
247.79M
247.79M – 247.79M
+18.4% YoY
|
| EBIT |
129.81M
est: 140.49M (-7.6%)
|
103.18M
est: 165.37M (-37.6%)
|
195.31M
195.31M – 195.31M
+18.1% YoY
|
231.24M
231.24M – 231.24M
+18.4% YoY
|
| Net Income |
113.00M
est: 125.80M (-10.2%)
|
89.60M
est: 123.72M (-27.6%)
|
144.52M
144.52M – 144.52M
+16.8% YoY
|
165.31M
165.31M – 165.31M
+14.4% YoY
|
| SGA |
23.16M
est: 31.39M (-26.2%)
|
20.47M
est: 36.94M (-44.6%)
|
43.63M
43.63M – 43.63M
+18.1% YoY
|
51.66M
51.66M – 51.66M
+18.4% YoY
|
| EPS |
1.07
est: 1.21 (-11.6%)
|
0.85
est: 1.19 (-28.6%)
|
1.39
1.39 – 1.39
+16.8% YoY
|
1.59
1.59 – 1.59
+14.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guo Li | Financial Director, Accounting Supervisor & Director | — | male |
| Hai Wang | GM & Director | — | male |
| Jiahong Zhang | Board Secretary | — | male |
| Xiaofeng Gu | Deputy GM & Director | — | male |
| Yanbin Pei | Deputy General Manager | — | male |
| Zhonghui Ding | Deputy GM & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688338.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
